Charles River and Distributed Bio enter exclusive partnership to create an integrated antibody discovery and development platform

This partnership will grant Charles River’s clients access to Distributed Bio’s antibody libraries and integrated antibody optimisation technologies. Distributed Bio’s libraries are computationally optimised for both sequence diversity and engineering fitness through the analysis of thousands of human antibody repertoires and all known monoclonal therapeutics in clinical trials. A combination of Distributed Bio’s antibody libraries and Charles River’s extensive drug development expertise will create a unique end-to-end platform for therapeutic antibody discovery and development.

Advanced Human Antibody Libraries

Distributed Bio’s computational immunoengineering platform provides libraries that can generate more than 5,000 unique hits against every antigen tested. This platform improves the chance of successful hit finding, reduces optimisation requirements, and expedites the discovery process to as little as three to four months. Distributed Bio’s computational immunology expertise also enables optimisation of existing client antibodies generated through more traditional platforms, such as hybridoma or traditional phage display.

With a focus on speed and design, this partnership will help increase the probability of success for delivering high-quality antibody candidates.

Approved Quotes

• “Distributed Bio’s technology, coupled with Charles River’s deep scientific strength in drug discovery and early-stage development, ensures that our portfolio is truly next generation. This combination provides our clients with Distributed Bio’s ability to discover new antibodies, then proceed seamlessly from hit to clinical candidate faster than before.” – Birgit Girshick, Corporate Executive Vice President of Discovery and Safety Assessment at Charles River.
• “Charles River is the premier, early-stage contract research organisation with a global reach and a track record of excellence. Leveraging our revolutionary antibody discovery and engineering platforms and Charles River’s downstream capabilities will deliver a comprehensive research experience from idea to clinic. We are about to release the third generation of our discovery platform and sought a partner that had both the scale to match our growth and the agility to realise the value of our antibody platforms as fast as possible.” -Jake Glanville, Ph.D., Founding Partner and Chief Science Officer at Distributed Bio.

To learn more about Charles River, visit www.criver.com.